Prenatal alcohol exposure reprograms physiological systems {#S0001}
==========================================================

Adverse early-life conditions have the potential to permanently imprint or program physiological and behavioral systems during development and lead to long-term consequences in offspring \[[@B1],[@B2]\]. In particular, epigenetic mechanisms are emerging as potential mediators for the biological embedding of these experiences, as they provide a link between *in utero* conditions and the genome in the modulation of subsequent developmental trajectories \[[@B3],[@B4]\]. Prenatal alcohol exposure can result in an adverse *in utero* environment that causes numerous adverse developmental consequences. Fetal alcohol spectrum disorder (FASD) refers to the broad spectrum of structural, neurocognitive, physiological and behavioral abnormalities or deficits that can occur following prenatal alcohol exposure (PAE) \[[@B5],[@B6]\]. At the most severe end of the spectrum is fetal alcohol syndrome (FAS), which can occur with chronic exposure to high doses of alcohol \[[@B7]\]. The diagnostic criteria for FAS consist of pre- and postnatal growth retardation, a characteristic facial dysmorphology and central nervous system (CNS) alterations, including neurological abnormalities, developmental delays and intellectual impairment \[[@B6]\]. Exposure to alcohol at levels that do not produce full FAS can result in either partial FAS, where only some of the diagnostic features occur, or in numerous alcohol-related effects that can be primarily physical (alcohol-related birth defects) or primarily neurobehavioral (alcohol-related neurodevelopmental disorder). Of note, alcohol-related birth defects and alcohol-related neurodevelopmental disorder are not mutually exclusive and both may occur in an individual exposed to alcohol *in utero* \[[@B6]\].

The degree to which alcohol affects development depends on a variety of factors such as timing and level of alcohol exposure, overall maternal health and nutrition, and genetic background \[[@B8]\]. However, neurobehavioral/neurodevelopmental deficits are consistently seen across the spectrum, and include neurocognitive impairment (cognitive function, learning and memory, executive function), impairment in self-regulation (attention, impulsivity, behavioral regulation, stress responsiveness, mood/affect, sleep abnormalities) and deficits in adaptive function (communication, social behavior, activities of daily living) \[[@B9]\]. Importantly, the adverse neurodevelopmental outcomes of children with FASD often persist well into adulthood, including metabolic changes, immune dysfunction, and altered stress responsitivity (reviewed in \[[@B15]\]).

Animal models of PAE were first developed in response to the skepticism that greeted the first description of FAS by Jones and Smith (1973) \[[@B16]\]. These were particularly important to the field, as they provided a level of control not possible in the clinical setting and allowed for the analysis of deficits associated with timing, pattern (acute vs chronic) and dose of alcohol, genetic factors, environment, nutrition and interactions with other drugs. An additional important strength of animal models is the ability to make direct correlations between central and peripheral tissues, as clinical studies do not have ready access to critical tissues such as the brain and other organs, except through biopsy, and changes in clinically accessible tissues do not always reflect alterations in the brain. Furthermore, animal models can provide critical insight into the molecular mechanisms underlying effects of PAE, and can thus pave the way for identification of novel biomarkers. Important recent studies have made significant progress in characterizing the neurodevelopmental, physiological, and behavioral alterations associated with PAE, as well as elucidating molecular mechanisms through which these alterations occur at different doses and patterns of alcohol exposure. *In vitro* studies have provided further vital insights into the molecular mechanisms by which alcohol affects cellular functions, allowing for the dissection of molecular pathways in highly specific and controlled environments \[[@B17]\]. These different strategies have provided key insights into the altered neurodevelopmental profiles resulting from PAE and highlight the complex and long-term programming effects of alcohol on numerous developmental processes. Taken together, these studies provide support for the suggestion that the underlying adverse effects of PAE on development may involve fetal programming. This concept suggests that early environmental or nongenetic factors, including maternal undernutrition, stress, and exposure to drugs or other toxic agents, can permanently organize or imprint physiological and neurobiological systems to increase adverse cognitive, adaptive and behavioral outcomes, as well as vulnerability to diseases or disorders later in life \[[@B1],[@B2],[@B23]\]. Of particular relevance, research has shown that alcohol is an early life insult that programs developing neurobiological systems and markedly increases risk for adverse outcomes \[[@B24]\]. Although the exact molecular mechanisms underlying these effects remain unknown, epigenetics is a prime candidate for the programming effects of environmental factors on physiological systems, as it might serve as a link between environmental stimuli and neurodevelopmental outcomes to influence health and behavior well into adulthood \[[@B25]\].

Epigenetic reprogramming by developmental alcohol exposure {#S0002}
==========================================================

Epigenetics refers to modifications of DNA and/or its regulatory factors, including chromatin and noncoding RNA, that alter the accessibility of DNA to modulate gene expression and cellular functions without changes to underlying genomic sequences \[[@B28]\]. Patterns of epigenetic modifications, in general, have been closely associated with cell fate specification and differentiation, suggesting a crucial role for epigenetics in the regulation of cellular functions \[[@B29]\]. Notably, cell specificity is the major driver of global epigenetic patterns, as each cell type is associated with a unique epigenomic landscape. In addition to the stability of the epigenome in regulating cellular identity, epigenetic patterns can also be influenced by environmental stimuli, although these effects tend to be subtler. Importantly, epigenetic mechanisms exist in a seeming paradox between the stability of cellular identity and plasticity of environmental responses, modulating cellular functions through both short- and long-term responses to stimuli \[[@B4]\].

Given the close relationship between gene expression and epigenetic patterns, it is not surprising that initial evidence of the programming effects of alcohol on the genome were identified through changes in transcription. A number of key studies have demonstrated that alcohol exposure during gestation leads to persistent genome-wide alterations to the transcriptome \[[@B30]\]. Indeed, PAE causes widespread changes to gene expression levels in the brain of fetal, neonatal and adult rodents \[[@B18],[@B31],[@B35],[@B36]\]. Importantly, we have shown that changes in gene expression occur not only under basal conditions, but also in the transcriptomic responses to an immune challenge in PAE compared with control animals, highlighting the robust long-term reprogramming of transcriptomic profiles in the brains of PAE animals \[[@B34]\]. Although the relationship between gene expression and epigenetic patterns remains extremely complex, these findings suggest that PAE-induced deficits may be associated with reprogramming of the epigenome during development \[[@B27]\]. Indeed, numerous lines of evidence now point to epigenetic alterations in the etiology of FASD, including evidence from cell culture, various animal models of prenatal and neonatal alcohol exposure, as well as a few recent clinical studies of FASD. [Figure 1](#F0001){ref-type="fig"} provides an overview of our take on fetal programming of physiological systems by developmental alcohol exposure. Of note, many studies have used either FASD phenotypes or exposure paradigms as their main focus when assessing epigenetic changes. Here, we delineate the current state of epigenetic research in FASD, which includes investigation of DNA modifications, chromatin alterations and ncRNA expression profiles, highlighting the role of epigenetics in the reprogramming of biological systems by PAE.

![**Overview of the mechanisms underlying fetal programming by prenatal alcohol exposure.**\
Ethanol exposure can have both direct effects on cellular programs through intracellular pathways, and indirect effects through the stimulation of various physiological systems, which release signaling molecules that can affect cellular functions. Cell death may play a role in the reprogramming of physiological systems, but is not depicted here. Together, these likely play a role in the biological embedding of PAE, with long-term consequences on health and behavior. Importantly, epigenetic mechanisms may mediate these effects through ethanol-dependent alterations in chromatin states. Chromatin, located in the cell's nucleus, dynamically influences gene expression to modulate cellular functions. Transcriptionally active epigenetic states involve the presence of pro-transcriptional histone modifications and gene body DNA methylation. Micro-RNA (miRNA) provide an additional layer of regulation by modulating protein levels through translational inhibition. By contrast, transcriptionally inactive chromatin landscapes are associated with promoter DNA methylation, which can inhibit transcription factor binding and recruit methyl-binding proteins that promote anti-transcriptional histone modifications through their association with histone-modifying complexes. Nevertheless, the relationship between epigenetic states and transcription remains extremely complex, and this figure is merely a simplified representation of epigenetic regulation (expanded from our previous review \[[@B27]\]).](epi-09-291-g1){#F0001}

PAE is correlated with altered DNA modification programs throughout the lifespan {#S0003}
--------------------------------------------------------------------------------

Covalent modifications of DNA nucleotides have long been established as a form of epigenetic regulation, and include both DNA methylation and hydroxymethylation. DNA methylation is perhaps the most studied epigenetic modification and involves the covalent attachment of a methyl group to the 5′ position of cytosine, typically occurring at cytosine-guanine dinucleotide (CpG) sites \[[@B37]\]. As CpG dinucleotides are palindromic, both DNA strands are generally methylated at CpGs, allowing for conservation of DNA methylation patterns during cell division \[[@B22]\]. Additionally, recent evidence suggests that DNA methylation also occurs at low levels at CpH sites (where H = A, C or T), which is found at high levels in the brain, particularly within neurons \[[@B39],[@B40]\]. DNA methylation is associated with the regulation of gene expression, although its effects on transcription are highly dependent on genomic context \[[@B38]\]. For example, DNA methylation at gene promoters generally represses gene expression, while its role is more variable within gene bodies and intergenic regions \[[@B38]\]. DNA methylation can also directly control the binding of transcription factors and repressors to gene regulatory regions, such as promoters and enhancers, to modulate gene expression patterns \[[@B41]\]. In addition to its role in transcriptional control, DNA methylation within exon--intron boundaries has been associated with altered mRNA splicing, and its presence within certain exons potentially regulates alternative transcriptional start sites \[[@B42]\]. Although DNA methylation patterns at promoters within an individual tend to negatively correlate with gene expression, emerging evidence shows that when comparing a single gene across a population, the association between DNA methylation and gene expression can be negative, positive or nonexistent, highlighting the complex relationship between DNA methylation and transcription \[[@B45]\]. In contrast to DNA methylation, hydroxymethylation of cytosine residues is thought to act as an intermediate in the active demethylation cycle of DNA by the TET family of enzymes. However, recent studies have shown that DNA hydroxymethylation may also play a role in the regulation of gene expression through the recruitment of various chromatin modifiers \[[@B48]\]. Moreover, given its high levels in pluripotent cells and the adult brain, DNA hydroxymethylation may also potentially have a functional role in neurodevelopment and various cognitive processes \[[@B39],[@B49]\]. Perhaps most importantly, in addition to its role in the regulation of developmental programs, DNA methylation is also emerging as a potential biomarker for early-life exposures due to its stability over time and malleability in response to environmental cues \[[@B54]\].

A large number of studies have identified changes in DNA modifications in response to PAE, and the current review will present a snapshot of the different approaches to assess these alterations, which range from 'bulk' levels to candidate gene approaches and genome-wide investigations (here, we define bulk levels as measures of epigenetic patterns that do not delineate specific regions, but rather represent the total levels within a given tissue or cell population). For a detailed overview of all current studies of DNA modifications and developmental alcohol exposure, please refer to [Table 1](#T1){ref-type="table"}. The first evidence of alcohol-induced changes to DNA methylation programs was generated in a mouse model, where embryos were exposed to alcohol during gestational days (GD) 9--11. This study demonstrated that alcohol reduced bulk levels of DNA methylation in the genome, potentially by inhibiting DNMT1 activity, and opened the door for future studies of epigenetic mechanisms in FASD \[[@B55]\]. Several studies have extended this line of evidence by studying the effects of alcohol exposure during various stages of development and identifying alterations to bulk levels of DNA methylation in different brain regions under basal and intervention conditions ([Table 1](#T1){ref-type="table"}) \[[@B56]\] For instance, PAE throughout gestation delays the accumulation of DNA methylation in neural stem cells, and increases DNA methylation levels in the mouse hippocampus, a brain region involved in learning and memory \[[@B58]\]. This same study assessed bulk DNA hydroxymethylation in parallel, identifying a decrease in the neural progenitor cells of the hippocampus, which suggests widespread alterations to DNA methylation programs \[[@B58]\]. In addition to assessing the impact of PAE on bulk DNA methylation levels, a number of studies have used bulk DNA methylation levels as a measurable outcome for dietary or therapeutic interventions in combination with different behavioral tasks. For example, choline supplementation has been proposed as a potential intervention due to its role as a methyl donor, and has been associated with the partial rescue of behavioral alterations and increased DNA methylation levels in the hippocampus and prefrontal cortex of PAE rats \[[@B56],[@B62]\]. Similar outcomes are also observed in embryos and neural stem cells treated with alcohol or 5-azacytidine, a potent inhibitor of DNA methylation, suggesting that alcohol-induced deficits are likely related to altered epigenomic profiles and functions \[[@B18]\]. Overall, these findings demonstrate that developmental alcohol exposure tends to impair the establishment of typical DNA methylation levels, which may reprogram downstream cellular and biological functions.

###### **DNA modification studies of developmental alcohol exposure.**

  **Type**      **Exposure paradigm**   **Model**                        **Effects**               **Ref.**                                                                                                                                                                                                                                                                                       
  ------------- ----------------------- -------------------------------- ------------------------- ------------- -------------- -------------------------------- -------------------------------------------------- ------------ ------------- ----------------------------------------------------------------------------------------- -------------------------------------------------------- ------------
  Bulk          A                       3 g/kg (2×/day)                  Gavage                    GD 9--11      Mouse          Whole fetus                      N                                                  GD 11        ND            ↓                                                                                         DNA methylation                                          \[[@B55]\]
                                                                                                                                                                                                                                               ↓                                                                                         DNMT1 activity                                            
                A                       3 g/kg (1×/day)                  Intragastric intubation   PN 2--10      Rat            Hippocampus/prefrontal cortex    N                                                  PN 21        Male/female   ↑                                                                                         DNA methylation                                          \[[@B56]\]
                A                       4.5 g/kg                         Gavage                    GD 1--22      Rat            Hippocampus                      N                                                  PN 21        Male/female   ↑                                                                                         DNMT activity                                            \[[@B57]\]
                M                       4% v/v ethanol                   Liquid diet               GD 1--17      Mouse          Hippocampus                      N                                                  GD 17        ND            ↑                                                                                         DNAm/DNAhm of CA1 cells, intermediate zone (DNAm only)   \[[@B58]\]
                                                                                                                                                                                                                                               ↓                                                                                         DNAm/DNAhm of NE                                          
                                                                                                                                                                                                                    PN 7         ND            ↑                                                                                         DNAm of outer granule layer                               
                                                                                                                                                                                                                                               ↓                                                                                         DNAhm of outer and inner granule layer cells              
                A                                                                                                                                                                                                                                                                                                                                                                                  
                                        200 mM                           2 days                    NA            Mouse          Embryonic fibroblast (NIH/3T3)   Y                                                  GD 13.5      ND            ↓                                                                                         DNA methylation                                          \[[@B59]\]
                                                                                                                                                                                                                                               ↓                                                                                         *Dnmt1, Dnmt3a, Dnmt3b* levels                            
                A                                                                                                                                                                                                                                                                                                                                                                                  
                                        2.5 g/kg (2× at 0 h and 2 h)     Subcut. injection         PN 7          Mouse          Hippocampus and neocortex        N                                                  PN 7         Male/female   ↓                                                                                         DNA methylation                                          \[[@B60]\]
                                                                                                                                                                                                                                               ↓                                                                                         *Dnmt1, Dnmt3a* levels                                    
                A                       70 mM                            8 days                    GD 14.5       Mouse          Neural stem cells                Y                                                  NA           NA            ↑                                                                                         DNA methylation                                          \[[@B61]\]
  Targeted      M                       5.0 g/kg                         Liquid diet               GD 1--18      Rat            Astrocyte                        Y                                                  GD 21        Male/female   ↑                                                                                         *Gfap* DNA methylation                                   \[[@B65]\]
                A                       6.0 g/kg                         Intragastric intubation   GD 1--20      Rat            Olfactory bulb                   N                                                  PN 10        Male/female   ↑                                                                                         *Bdnf* DNA methylation                                   \[[@B66]\]
                M                       10% v/v ethanol                  Free drinking             GD 0.5--8.5   Agouti mouse   Tail                             N                                                  PN 21        Male/female   ↑                                                                                         A^vy^ IAP DNA methylation                                \[[@B64]\]
                A                       5.8 g/kg                         Intragastric intubation   GD 9          Mouse          Embryo                           N                                                  GD 17        Male          ↓                                                                                         *Igf2* DNA methylation                                   \[[@B67]\]
                                                                                                                                                                                                                                               ↑                                                                                         *Igf2* expression                                         
                M                       6.7% v/v ethanol                 Liquid diet               GD 7--21      Rat            Mediobasal hypothalamus          N                                                  PN 60--65    Male          ↑                                                                                         *Pomc* DNA methylation                                   \[[@B68]\]
                M                       10% v/v ethanol                  Free drinking             GD 0.5--8.5   Mouse          Hippocampus                      N                                                  PN 87        Male          ↓                                                                                         *Vglut2* DNA methylation                                 \[[@B69]\]
                M                       10% v/v ethanol                  Free drinking             GD 0.5--8.5   Mouse          Hippocampus                      N                                                  PN 28        Male          ↑                                                                                         DNAm *Vmn2r64, Olfr110* (2 CpG)                          \[[@B71]\]
                                                                                                                                                                                                                                               ↓                                                                                         DNAm *Olfr601, Olfr110* (1 CpG)                           
                A                       70 mM                            8 days                    GD 14.5       Mouse          Neural stem cells                Y                                                  NA           NA                                                                                                      DNAm *MeCP2*                                             \[[@B61]\]
                M                       35.5% ethanol-derived calories   Liquid diet               GD 1--22      Rat            Hippocampus                      N                                                  PN 55        Male/female   ↑                                                                                         DNAm *Slc6a4*                                            \[[@B70]\]
  Genome wide   A                       400 mg/dl                        44 h                      GD 8.25       Mouse          Embryo                           Y                                                  GD 10        ND            ↑                                                                                         1028 genes DNA methylation                               \[[@B17]\]
                                                                                                                                                                                                                                               ↓                                                                                         1136 genes DNA methylation                                
                A                       400 mg/dl                        2 days                    NA            Mouse          NS-5 neural stem cells           Y                                                  NA           ND            ↑                                                                                         DNAm in 83 cell cycle genes                              \[[@B19]\]
                A                       400 mg/dl                        6 h                       NA            Rat            DRG-derived neural stem cells    Y                                                  NA           ND            ↓                                                                                         NSC gene DNAm                                            \[[@B72]\]
                M                       20 mM                            4 days                    NA            Human          Embryonic stem cells             Y                                                  NA           ND            No changes in DNA methylation at 27,000 CpGs                                              \[[@B74]\]                                               
                M                       10% v/v ethanol                  Free drinking             GD 1- PN10    Mouse          Whole brain                      N                                                  PN 70        Male          6660 differentially methylated promoters                                                  \[[@B73]\]                                               
                M or A                  20 mM or 50 mM                   1 or 2 days               NA            Human          Embryonic stem cells             Y                                                  NA           Male/female   DNA hypermethylation at TSS and CpG islands, but inconsistent across individual regions   \[[@B75]\]                                               
                A                       2.5 g/kg (2× at 0 and 2 h)       Subcut. injection         PN 4,7        Mouse          Hippocampus                      N                                                  PN 70        Male          4640 differentially methylated regions in gene promoters and 459 in CpG islands           \[[@B76]\]                                               
                Confirmed FASD          Human                            Buccal epithelial cells   N             3--6 years     Male                             269 differentially methylated CpGs                 \[[@B77]\]                                                                                                                                                                    
                Confirmed PAE           Human                            Buccal epithelial cells   N             5--18 years    Male/female                      356 hypomethylated CpGs 302 hypermethylated CpGs   \[[@B78]\]                                                                                                                                                                    

A: Acute; DNAm: DNA methylation; DNAhm: DNA hydroxymethylation; GD: Gestational day; M: Moderate; NA: Not applicable; ND: Not disclosed; NE: Neuroepithelium; PN: Postnatal day.

Proof of principle of alcohol's programming effects was further exemplified using the agouti viable (A^vy^) yellow mouse model, which contains a DNA methylation-sensitive element within the A^vy^ locus that regulates coat color \[[@B63]\]. In this model, PAE increased the incidence of pseudo-agouti animals, indicating that specific loci are responsive to the effects of alcohol during development and can influence phenotypic outcomes \[[@B64]\]. As such, more recent studies have sought to identify specific gene targets of PAE-induced epigenetic effects, either through hypothesis- or discovery-driven approaches. An initial study using cultured cells showed that, rather than a global demethylation of the genome, specific regions become more methylated and others less methylated in response to alcohol exposure, suggesting that some regions may be differentially sensitive to alcohol-induced reprogramming effects \[[@B17]\]. Consequently, numerous groups have invested in targeted analyses of epigenetic patterns in genes associated with the deficits observed in individuals with FASD (e.g., immune, stress, cognitive and otherwise-related; [Table 1](#T1){ref-type="table"}) \[[@B61],[@B65]\]. For instance, in mice, the expression of *Igf2*, an imprinted gene involved in growth, is decreased in the embryo and placenta following PAE, concomitant with increased DNA methylation of the differentially methylated region 1 in its promoter and growth deficits in offspring. Interestingly, choline supplementation during gestation partially rescues the effects of PAE on growth and DNA methylation within this locus, further highlighting a potential role for dietary supplements in the attenuation of alcohol-induced deficits \[[@B67]\]. PAE also results in increased DNA methylation and decreased expression of proopiomelanocortin in the hypothalamus, which is a key regulator of the stress response \[[@B68]\]. Moreover, we have shown that *Slc6a4*, an important serotonin transporter, also displays sex-dependent alterations to DNA methylation and gene expression patterns in the hypothalamus of adult PAE rats \[[@B70]\]. While the hypothesis-driven approach has proven fruitful in many regard, it relies heavily on previously identified biological pathways and has not been very successful in identifying novel targets of developmental alcohol exposure.

More recently, researchers have begun using genome-wide tools to study the effects of alcohol exposure beyond classical candidate pathways ([Table 1](#T1){ref-type="table"}) \[[@B17],[@B19],[@B72]\]. For example, widespread changes in DNA methylation patterns were identified in the brains of adult male mice, with some alterations overlapping with changes in gene expression profiles \[[@B73],[@B76]\]. In addition to the identification of new genes potentially associated with alcohol exposure, these findings provide evidence for the lasting effects of developmental alcohol exposure on the DNA methylome. Moreover, these PAE-related changes in the DNA methylome may, in turn, alter transcriptional profiles and reprogram physiological systems. Two recent studies have also characterized the DNA methylation profile of buccal epithelial cells (BECs) of children with FASD, identifying widespread alterations to the epigenome, and have provided preliminary evidence of a DNA methylation 'signature' of FASD \[[@B77],[@B78]\]. Specifically, this study identified alterations in novel genes, as well as in genes previously associated with alcohol exposure, including several imprinted genes and the protocadherin clusters \[[@B78]\]. While the use of a peripheral tissue, BECs, makes it difficult to readily interpret these findings in the context of FASD-associated deficits, these studies provide important insight into potential biomarkers of PAE in human populations. Nevertheless, additional cohorts from different cultural backgrounds are necessary to validate these findings and solidify their usefulness in a clinical context.

Taken together, these studies highlight the widespread effects of developmental alcohol exposure on DNA methylation patterns, although the direction of change varies depending on the model of alcohol exposure, the tissue analyzed and the specific genes assessed. While most studies of bulk DNA methylation identify a decrease in methylation levels, potentially due to lower activity of DNMTs and the inhibition of 1-carbon metabolism by alcohol, results have varied across models due to a number of factors, including differences in levels and timing of alcohol exposure, developmental stage, analyzed tissue and analysis methods. These findings highlight the importance of using different models to assess the molecular mechanisms underlying the effects of ethanol at different stages, doses, etc. Furthermore, the analysis of DNA hydroxymethylation in the context of FASD remains an elusive topic of research, only investigated in a single study of PAE \[[@B58]\]. Given its seemingly key role in neurons, it could potentially play an important role in the etiology of FASD. As a whole, multiple lines of evidence support a role for DNA methylation in the fetal programming of biological systems by PAE and represent an important avenue for the discovery of biomarkers of FASD.

Chromatin modifications associated with PAE {#S0004}
-------------------------------------------

In eukaryotic genomes, DNA is found in nucleoprotein polymers known as chromatin, which compact DNA within the nucleus and modulate access to genetic material. More specifically, DNA is wrapped around nucleosomes, protein octamers containing two molecules each of core histone proteins H2A, H2B, H3 and H4 \[[@B79],[@B80]\]. The flexible N-terminal tails of these proteins are the main targets for histone modifications, which control chromatin structure and transcription by modulating the accessibility of the local chromatin structure. Different histone modifications may regulate transcription in their vicinity by serving as a docking platform to recruit various effector proteins -- such as chromatin remodeling complexes -- or by preventing various proteins from binding to chromatin \[[@B81]\]. The different types of histone marks include acetylation, methylation, phosphorylation, ubiquitination, sumoylation and ADP-ribosylation, which play various functional roles depending on their cellular context and location on the histone tail \[[@B82]\]. For instance, histone acetylation and histone H3 lysine 4 (H3K4) methylation are typically associated with increased transcription, while methylation of histone H3 lysine 9 (H3K9) and 27 (H3K27) is associated with transcriptional repression. Importantly, histone modifications play a crucial role in mediating the crosstalk between transcriptional regulation and chromatin-modifying enzymes to dynamically regulate chromatin structure, downstream transcriptional activity and cellular programs \[[@B83]\]. Additional relevant chromatin-associated proteins include methylated DNA-binding proteins, such as MeCP2, and the methyl CpG-binding (MBD) domain family of proteins. These can act as intermediaries between DNA and histone modifications, recruiting histone-modifying enzymes to modulate the chromatin landscape \[[@B38],[@B85]\]. In particular, they have been tightly associated with development, and mutations in MeCP2 lead to a severe neurodevelopmental disorder, Rett syndrome, suggesting that they may play a role in mediating the effects of PAE \[[@B86],[@B87]\].

To date, the effects of developmental alcohol on chromatin structure have been relatively understudied. Again, we present a broad overview of the different approaches to studying histone modifications following PAE, including the investigation of bulk levels, targeted genes and genome-wide associations. [Table 2](#T2){ref-type="table"} delineates the different studies assessing chromatin alterations following developmental alcohol exposure. The earliest evidence of alcohol-induced changes to chromatin proteins came from a sheep model of chronic PAE, where fetal sheep display lower levels of H2A family proteins compared with controls \[[@B88]\]. Furthermore, several genome-wide studies of PAE have identified differences in the expression of histone modifying enzymes and enrichment of gene ontology terms associated with chromatin proteins \[[@B32]\]. Together, these findings suggest that alcohol exposure during development could potentially impact the abundance of different chromatin proteins, leading to fundamental alterations to chromatin structure and function. More recent studies have focused primarily on the bulk levels of histone modifications following PAE ([Table 2](#T2){ref-type="table"}) \[[@B68],[@B89]\]. For instance, exposure to high levels of alcohol during the 'third-trimester equivalent' (PN 7) rat model causes reductions in bulk levels of acetylated histone H3 and H4 in the cerebellum, suggesting a global decrease in transcriptional activity \[[@B89]\]. Similar results were found using a prenatal exposure model, where a more repressed chromatin state was found in the brains of adult male rats exposed throughout gestation (equivalent to the first two trimesters of human pregnancy). These animals show decreased bulk levels of total H3K4 di- and trimethylation and H3K9 acetylation, as well as an increase in H3K9 dimethylation, concomitant with altered expression profiles of the chromatin-modifying enzymes, *Set7/9, Setdb1, Hdac2* and *G9a*, which modulate the levels of these marks. Together, these findings support a role for alcohol in long-lasting effects on the regulation of chromatin states \[[@B91]\].

###### **Studies of chromatin alterations in response to developmental alcohol exposure.**

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Type**                  **Exposure paradigm**   **Model**                    **Effects**               **Ref.**                                                                                                                                                                                                                                                                                                                
  ------------------------- ----------------------- ---------------------------- ------------------------- -------------- ------------------- -------------------------------------------------------------- --- ----------------------- ------------- ------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------- -------------
  Bulk                      M                       4 h/day                      Inhalation chamber        PN\            Rat                 Cerebellum                                                     N   PN 2, 4, 6, 8, 10, 12   Male/female   ↓                                                                                          H3ace, H4ace, H3K23ace                                                           \[[@B89]\]
                                                                                                           2--12                                                                                                                                                                                                                                                                                                                   

                                                                                                                                                                                                                                                       ↑                                                                                          *Cbp* expression (not PN10,12)                                                    

                            M or A                  50 or 200 mM ethanol         24 h                      NA             Mouse               Cardiac progenitor cells                                       Y   NA                      ND            ↑                                                                                          H3K9ace                                                                          \[[@B90]\]

                            M                       6.7% v/v ethanol             Liquid diet               GD\            Rat                 POMC neurons of the arcuate nucleus                            N   PN 60--80               Male/female   ↑                                                                                          H3K9me2, G9a, *Hdac2, Setdb1* expression                                         \[[@B91]\]
                                                                                                           7--21                                                                                                                                                                                                                                                                                                                   

                                                                                                                                                                                                                                                       ↓                                                                                          H3K4me2/3, H3K9ace\                                                               
                                                                                                                                                                                                                                                                                                                                                  *Set7/9* expression                                                              

                            A                       262.5 mM                     24 h                      48--72 hpf     Zebrafish           Embryo                                                         N   72 hpf                  Male/female   ↑                                                                                          Phosphorylated histone H3                                                        \[[@B96]\]

                            M                       6.7% v/v ethanol             Liquid diet               GD\            Rat                 β-endorphin neurons of the arcuate nucleus                     N   PN 60--65               Male          ↑↓                                                                                         H3K9me2 H3K4me2/3, H3K9ace, H3S10phospho                                         \[[@B68]\]
                                                                                                           7--21                                                                                                                                                                                                                                                                                                                   

                            A                       2.5 g/kg (2× at 0 and 2h)    Subcut. injection         PN 7           Mouse               Hippocampus & Neocortex Neocortex                              N   PN 7                    Male/female   ↑                                                                                          H3K9me2, H3K27me2                                                                \[[@B92]\]

                                                                                                                                                                                                                                                       ↑                                                                                          *G9a* expression                                                                  

                            M                       1.0 g/kg (2× at 0 and 2 h)   Subcut. injection         PN 7           Mouse               Hippocampus & Neocortex                                        N   PN 7                    ND            ↑                                                                                          H3K9me2, H3K27me2                                                                \[[@B93]\]

                            A                       6 g/kg                       Intragastric intubation   GD\            Mouse               Fetal heart                                                    N   GD 14.5                 Male/female   ↑                                                                                          H3K14ace                                                                         \[[@B94]\]
                                                                                                           7--14.5                                                                                                                                                                                                                                                                                                                 

                            A                       5 g/kg                       Intragastric intubation   GD 8.5--16.5   Mouse               Fetal heart                                                    N   GD 14.5\                Male/Female   ↑                                                                                          H3K9ace                                                                          \[[@B95]\]
                                                                                                                                                                                                                 PN 7                                                                                                                                                                                                              

                            A                       5.0 g/kg (2× at 0 and 2h)    Subcut. injection         PN 7           Mouse               Cerebral cortex                                                N   PN 7                    Male          ↑                                                                                          H2AX serine 139 phosphorylation                                                  \[[@B97]\]

  Methyl-binding proteins   A                       200 mM                       2 days                    NA             Mouse               Embryonic fibroblast (NIH/3T3)                                 Y   GD 13.5                 ND            ↓                                                                                          *Mbd3* level                                                                     \[[@B59]\]

                            A                       6 g/kg (2× at 0 and 6h)      Intragastric intubation   GD 6--15       Mouse               Cortex & Striatum                                              N   5 weeks                 Male/female   ↓                                                                                          MeCP2 levels                                                                     \[[@B100]\]

                            A                       70 mM                        8 days                    GD 14.5        Mouse               Neural stem cells                                              Y   NA                      NA            ↑                                                                                          MeCP2 levels                                                                     \[[@B61]\]

                            A                       300 mM                       6 days                    0--6 dpf       *Oryzias latipes*   Brain                                                          N   6 dpf                   Male/female   ↑                                                                                          *Mecp2, Mbd1b, Mbd3a, Mbd3b*                                                     \[[@B101]\]

  Targeted                  A                       320 mg/dl                    5 days                    GD 12.5        Mouse               Fetal cerebral cortical neuroepithelial stem cells             Y   NA                      ND            ↓                                                                                          H3K4me3, H3K27me3 of NSC/hemeobox genes and transposable elements                \[[@B20]\]

                            M                       1.0 g/kg (2× at 0 and 2h)    Subcut. injection         PN 7           Mouse               Hippocampus and neocortex                                      N   PN 7                    ND            ↑                                                                                          H3K14ace of *G9a* exon 1                                                         \[[@B93]\]

                            A                       5 g/kg                       Intragastric intubation   GD 8.5--16.5   Mouse               Fetal heart                                                    N   GD 14.5\                Male/female   ↑                                                                                          H3K9ace of *Gata4* promoter                                                      \[[@B95]\]
                                                                                                                                                                                                                 PN 7                                                                                                                                                                                                              

                            A                       2.9 g/kg (2× at 0 and 4 h)   IP injection              GD 7           Mouse               Cortex                                                         N   GD 17                   ND            ↑                                                                                          H3K9ace of NSC/hemeobox genes                                                    \[[@B21]\]

                                                                                                                                                                                                                                                       ↓                                                                                          H3K27me3 of NSC/hemeobox genes                                                    

                            A                       160 or 240 mg/dl             3 days                    GD 12.5        Mouse               Fetal cerebral cortical neuroepithelial stem cells (GD 12.5)   Y   NA                      ND            ↑↓                                                                                         Dose-dependent alterations to H3K4me3, H3K9ace, H3K9me2, H3K27me3 in NSC genes   \[[@B21]\]

                            A                       2.5 g/kg (2× at 0 and 2 h)   Subcut. injection         PN 7           Mouse               Hippocampus and neocortex                                      N   PN 7                    ND            ↑↓                                                                                         H4K8ace of *Cb1r* exon 1 H3K9me2 of *Cb1r* exon 1                                \[[@B99]\]

                            M                       10% v/v ethanol              Free drinking             GD 0.5--8.5    Mouse               Hippocampus                                                    N   PN 87                   Male          ↑                                                                                          *Vglut2* H3K4me3                                                                 \[[@B69]\]

  Genome-wide               A                       2.5 g/kg (2× at 0 and 2 h)   Subcut. injection         PN 7           Mouse               Hippocampus                                                    N   PN 70                   Male          Widespread alterations to H3K4me3 (798 genes) and H3K27me3 (223 genes) -- little overlap   \[[@B76]\]                                                                       
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

A: Acute; Dpf: Day post-fertilization; GD: Gestational day; G-W: Genome-wide; Hpf: Hours past fertilization; M: Moderate; NA: Not applicable; ND: Not disclosed; PN: Postnatal day.

In addition to their roles in the regulation of transcriptional programs, histone marks can also serve as a proxy for DNA damage, as in the case of phosphorylation of serine 129 on histone H2AX (γH2AX), which is associated with double-stranded breaks and DNA fragmentation, a mark of apoptosis. Of note, the levels of this modification increase in the mouse cortex 7 h after alcohol exposure and may serve as a quantitative indicator of ethanol-induced DNA damage \[[@B97]\]. Several other histone modifications have also been associated with the high levels of neuroapoptosis observed after acute ethanol exposure. Extensive work has been performed related to the effects of developmental alcohol on H3K9 dimethylation and its association with ethanol-induced neurodegeneration, another mechanism through which PAE might reprogram physiological systems. Indeed, third-trimester equivalent exposure to alcohol increases the expression of G9a and induces a concomitant rise in bulk levels of dimethylated H3K9 and H3K27 in the neocortex and hippocampus. In turn, these are associated with caspase-3 activation and neuronal apoptosis in the postnatal day 7 brain of mice, potentially leading to long-term deficits in synaptic plasticity, learning, and memory \[[@B92],[@B98]\]. Interestingly, inhibition of G9a reduces the levels of neurodegeneration in these animals and may represent a potential intervention target for PAE \[[@B92],[@B98]\]. These results highlight the complex interplay among different mechanisms of fetal programming following alcohol exposure, placing epigenetic mechanisms at the nexus of different exposure paradigms and neurodevelopmental outcomes.

Similar to DNA methylation, the study of chromatin has also begun moving toward more specific target genes ([Table 2](#T2){ref-type="table"}) \[[@B20],[@B21],[@B69],[@B93],[@B95],[@B99]\]. For example, primary neurosphere cultures exposed to high levels of ethanol show alterations in H3K4 and H3K27 trimethylation within the regulatory regions of genes involved in differentiation and neural cell identity, as well as transposable elements \[[@B20]\]. Furthermore, in primary cultures of neural stem cells from mice, levels of H3K4 trimethylation, H3K27 trimethylation, H3K9 acetylation, and H3K9 methylation display dose-dependent alterations in response to ethanol exposure within the promoters of several genes involved in neuronal patterning \[[@B21]\]. These results highlight both the global effects of alcohol exposure on chromatin, and the importance of reconciling differences among the various models of alcohol exposure. Depending on the model, different genes exhibit differential histone modification profiles, which also shift between the immediate response to ethanol and 96 hours post-exposure, suggesting that the effects of alcohol are dependent on both the gene affected and the timing of exposure \[[@B21]\]. While the direction of alcohol-induced changes is variable across all modifications at different doses in this *in vitro* model, H3K9 dimethylation is consistently depleted compared with that in controls, contrasting studies of global H3K9 dimethylation levels. Furthermore, the same study also showed that exposure to alcohol on GD 7 alters histone modifications profiles of the same subset of neural patterning genes in the mouse cortex \[[@B21]\]. This finding supports the value of cell culture models in providing data relevant to those in *in vivo* models, and suggests that cell culture models could prove useful in the initial assessment of therapeutic interventions. Finally, genome-wide analysis of H3K4 and H3K27 trimethylation in the adult mouse brain revealed widespread differences in the enrichment profiles of ethanol-exposed animals compared with controls \[[@B76]\]. Although few overlaps between the enrichment patterns of the two modifications were identified, these findings nevertheless indicate long-term alterations to histone modification programs in the brain following PAE, which may have important ramifications in the assessment of functional deficits in FASD. Of note, this same study also investigated DNA methylation patterns, and similarly, found very few overlaps between alterations in the enrichment of histone marks and DNA methylation in response to alcohol exposure \[[@B76]\].

Overall, these findings suggest that alcohol exposure reprograms histone modifications both genome-wide and in a locus-specific manner, with different genes displaying unique patterns of epigenetic programming in response to alcohol. Overall, it appears that developmental alcohol exposure may generally promote a repressive epigenomic state at the bulk histone modification level, though the causative link between epigenetics states and gene expression remains unclear. However, as a vast number of different combinations exist in the histone code, the interpretation of these findings is extremely complex, especially given the number of different models of developmental alcohol exposure. More research is needed to assess additional histone modifications and their overlap throughout the genome, as well as their intersection with DNA modifications. Alcohol exposure also appears to influence the levels of methylated DNA-binding proteins, including MeCP2, MBD1 and MBD3, though the results vary across exposure paradigms \[[@B59],[@B61],[@B100],[@B101]\]. These findings reflect the complex interplay between DNA modifications and higher level chromatin structure, further highlighting the importance of integrating multiple levels of epigenetic mechanisms. Furthermore, variants of canonical histones may also play a role in the etiology of alcohol-induced deficits, and represent an intriguing avenue of research. Future studies should also strive to assess alterations to chromatin in human populations, as human research is lacking in this area, likely due to the difficulty of obtaining primary samples from human populations and the need for immediate sample fixation following collection for the targeted analysis of histone modifications. Although evidence of long-term effects on histone modification programs remains sparse, the data to date support a role for histone modifications in the reprogramming of biological systems by alcohol.

Noncoding RNA are associated with FASD phenotypes {#S0005}
-------------------------------------------------

Another layer of epigenetic regulation is mediated through ncRNAs, which are distinct from messenger RNA (mRNA) in that they are not translated into protein. These perform a wide variety of regulatory functions, ranging from the regulation of mRNA and protein levels to the repression of repetitive and transposable elements. For instance, micro-RNAs (miRNA) inhibit the translation of mRNA into protein, modulating the levels of different factors in the cell. By contrast, small nuclear RNA and small nucleolar (snoRNA) are involved in the post-transcriptional control of mRNA, mediating alternative splicing events and promoting post-transcriptional modifications of different RNA species. Finally, long non-coding RNAs (lncRNA) are emerging as key regulators of the cell, as they provide an essential layer of epigenetic control for several different processes. Specifically, lncRNAs act as guides for epigenetic repression or activation, decoys for chromatin modifying enzymes or RNAi pathways, and regulators of post-transcriptional RNA processing \[[@B102]\]. These transcripts also play important roles in the integration of developmental, spatial, temporal and stimulus-specific cues necessary for the integration of complex gene expression and epigenetic patterns required during development \[[@B106]\]. In the CNS, this additional level of epigenetic control appears to play a crucial role, as neurons express very high levels of ncRNAs, and the abnormal expression of several ncRNA species has been associated with various neurological disorders, including autism, Fragile X, Rett syndrome, schizophrenia and anxiety-like disorder \[[@B107]\].

Emerging evidence places ncRNA signaling at the nexus of brain development and alcohol-induced neurodevelopmental deficits. In particular, miRNAs have recently become an active area of research, particularly in the context of alcohol-induced neuroapoptosis and potential biomarkers of alcohol exposure \[[@B22],[@B69],[@B73],[@B117]\]. [Table 3](#T3){ref-type="table"} outlines the studies assessing miRNA expression patterns in response to developmental alcohol exposure. In contrast to DNA methylation and histone modifications, the first study of ncRNA was performed *in vitro*, using cultured neuroepithelial cells isolated from second-trimester mouse embryos \[[@B117]\]. These showed several differentially expressed miRNAs in response to ethanol treatment, including the suppression of miR-9, a crucial regulator of neurogenesis \[[@B117]\]. High doses of ethanol also cause levels of miR-9, miR-29a and miR-29b to decrease in primary cultures of cerebellar granule neurons isolated from PN 7 mice \[[@B125]\]. Importantly, miR-29b appears to mediate ethanol-induced apoptosis in this model and as a developmentally-regulated gene, could be involved in the cerebellum's period of alcohol sensitivity \[[@B125]\]. Furthermore, the decrease in miR-9 expression was replicated in murine neural stem cells, where it is associated with increased CpG dinucleotide methylation at the miR-9--2 locus, highlighting the interplay among the different layers of epigenomic regulation \[[@B121]\]. Chronic intermittent exposure of ethanol also causes widespread alterations in miRNA expression profiles in primary neuronal cells from GD 15 mice \[[@B126]\]. Interestingly, removal of ethanol in this model altered the expression of miRNAs involved in neuron differentiation, embryonic development and synaptic plasticity, suggesting that alcohol exposure can permanently reprogram the miRNome, and importantly, that withdrawal might also profoundly alter the epigenome of the cell \[[@B126]\].

###### **Micro-RNA studies of developmental alcohol exposure.**

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Exposure paradigm**                              **Model**                                **Effects**            **Ref.**                                                                                                                                                                                                                                                              
  -------------------------------------------------- ---------------------------------------- ---------------------- -------------- ----------- ------------------------------- --- ------------------------------------------------------------------------------------------- ------------- --- ---------------------------------------------------------------------------------------- -------------
  A                                                  320 mg/dl                                5 days                 GD 12.5        Mouse       Cerebral cortical NPC           Y   NA                                                                                          ND            ↓   9, 21, 153, 335                                                                          \[[@B117]\]

  L to A                                             2.0, 4.0 or 6.0 g/kg (2× at 0 and 2 h)   Gavage                 GD 6--15       Mouse       Fetal brain                     N   GD 17.5                                                                                     ND            ↑   9, 10a, 10b, 30a-3p, 145, 152                                                            \[[@B118]\]

                                                                                                                                                                                                                                                                                              ↓   29c, 30e-5p, 154, 200a, 296, 339, 362, 496                                                

  A                                                  1 or 1.5% ethanol                        NA                     4--24 hpf      Zebrafish   Embryo                          N   24 hpf                                                                                      ND            ↑   30d, 153a, 183, 736                                                                      \[[@B119]\]

                                                                                                                                                                                                                                                                                              ↓   23a                                                                                       

  A                                                  320 mg/dl                                5 days                 GD 12.5        Mouse       Cerebral cortical NPC           Y   NA                                                                                          ND            ↓   9, 21, 153, 335, 140--3p                                                                 \[[@B22]\]

  A                                                  2.5 g/kg (2× at 0 and 2 h)               Subcut. injection      PN 4, 7        Mouse       Whole brain                     N   PN 60                                                                                       Male          ↑   26b                                                                                      \[[@B120]\]

  A                                                  430 mM                                   NA                     3.5--7.5 hpf   Zebrafish   Embryo                          N   24, 48, 72 hpf                                                                              Male/female   ↑   pre-9--3 (precursor to 9)                                                                \[[@B121]\]

                                                                                                                                                                                                                                                                                              ↓   9                                                                                         

  M                                                  10% v/v ethanol                          Free drinking          GD 1 - PN 10   Mouse       Whole brain                     N   PN 70                                                                                       Male          ↑   679--5p                                                                                  \[[@B73]\]

  A                                                  400 mg/dl                                24 or 48 h             PN 7           Mouse       Cerebellar granule neurons      Y   PN 7                                                                                        ND            ↑   34a, 181a                                                                                \[[@B125]\]

                                                                                                                                                                                                                                                                                              ↓   9, 29a, 29b, 133                                                                          

  A                                                  2.5 g/kg (2× at 0 and 2 h)               Subcut injection       GD 14, 16      Mouse       Whole brain                     N   PN 70                                                                                       Male          ↑   302c                                                                                     \[[@B122]\]

  A                                                  2.9 g/kg at 0 h 1.45 g/kg at 2 h         IP injection           GD 12          Rat         Amygdala and ventral striatum   N   PN 42                                                                                       Male/female   ↑   34c, 155, 542--1, let-7c-1, let7c-2--3p                                                  \[[@B123]\]

                                                                                                                                                                                                                                                                                              ↓   9a-2, 29c-3p, 191--1, 138--2, 221--5p, 322--2, 384--5p, 412--3p, 496, 874--5p 1843a-3p    

  A                                                  1.75 g/kg (1 h/day × 3 days/week)        Intravenous catheter   GD\            Sheep       Plasma                          N   GD 147                                                                                      Male/female   ↑   34b                                                                                      \[[@B124]\]
                                                                                                                     4--132                                                                                                                                                                                                                                                                

                                                                                                                                                                                                                                                                                              ↓   9, 15b, 17--92, 572, 720                                                                  

  M                                                  10% v/v ethanol                          Free drinking          GD\            Mouse       Hippocampus                     N   PN 87                                                                                       Male          ↑   135a, 135b, 467b-5p, 487b                                                                \[[@B69]\]
                                                                                                                     0.5--8.5                                                                                                                                                                                                                                                              

  Heavily prenatally exposed and affected children   Human                                    Maternal plasma        N              NA          Female                          ↑   187--5p, 204--5p, 222--5p, 299--3p, 449, 491--3p, 518f-3p, 519a-3p, 671--5-. 760, 885--3p   \[[@B129]\]                                                                                                
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

A: Acute; GD: Gestational day; L: Low; Hpf: hours past fertilization; M: Moderate; NA: Not applicable; ND: Not disclosed; NPC: Neural progenitor cell; PN: Postnatal day.

*In vivo* rodent models of PAE have validated many of these findings and identified additional miRNAs associated with alcohol exposure. For instance, exposure to high levels of alcohol during early postnatal life decreases miR-29b expression in the mouse cerebellum, consistent with the observations from cultured cerebellar granule neurons \[[@B125]\]. Additionally, alcohol exposure from the mid-first to mid-second trimesters leads to widespread changes in miRNA levels in E17.5 mouse brains, including the upregulation of miR-10a and -10b, which regulate *Hoxa1*, a key factor during embryonic development \[[@B118]\]. This finding was partially replicated in adult mice, as acute alcohol exposure on GD14 and 16 also causes alterations to miRNA expression in the PN70 mouse brain, including miR-10b. This suggests that PAE may cause long-term reprogramming of ncRNA patterns, which may play a role in the functional deficits induced by alcohol \[[@B122]\].

Perhaps the best characterized miRNA in the context of alcohol exposure, miR-9 displays differential expression following developmental alcohol exposure across multiple models and ages. In addition to the *in vitro* models mentioned above, this finding has been replicated in both zebrafish embryos and newborn lambs \[[@B121],[@B124]\]. As miR-9 plays a key role in both the developing and adult brain as a vital regulator of neural function and development, its altered expression patterns could potentially have lasting effects on physiological functions \[[@B127]\]. *In vivo* knockout of miR-9 in zebrafish results in the same juvenile swimming phenotype as that in alcohol-treated animals \[[@B121],[@B128]\]. Of note, knockdown of miR-153c also results in this phenotype, and thus it is possible that this miRNA is implicated in the facial dysmorphisms observed in FASD due to its role in the development of the craniofacial skeleton \[[@B128]\]. Finally, the ovine model of alcohol exposure also identified a number of plasma miRNA in pregnant ewes and newborn lambs exposed to alcohol, including miR-9, miR-15b, miR-19b and miR-20a \[[@B124]\]. Given their high sensitivity and specificity for alcohol exposure, these miRNAs may represent potential biomarkers of alcohol exposure or key mediators of alcohol-induced epigenetic reprogramming. Indeed, a recent study showed that changes in plasma miRNAs in alcohol-exposed pregnant mothers could predict infant outcomes either alone or in conjunction with other clinical variables \[[@B129]\]. These findings suggest that maternal plasma miRNAs may be useful to classify difficult-to-diagnose FASD subpopulations, although further validation in independent cohorts is required.

In contrast to miRNA, few other ncRNA have been assessed in different models of developmental alcohol exposure. It was shown that first, second or third trimester equivalent exposure to alcohol increases *MBII-52*-specific snoRNA expression in the PN70 mouse brain \[[@B73]\]. This finding represents the only evidence of PAE-induced alterations to snoRNA expression to date and represents a promising avenue of research. Moreover, only a single differentially expressed lncRNA following developmental alcohol exposure, linc1354, has been identified to date. Associated with neural stem cell differentiation, this lncRNA shows decreased levels in neurosphere stem cells following ethanol exposure, supporting a role for lncRNAs in FASD \[[@B20]\]. While a wide variety of additional ncRNA species have not yet been assessed in PAE models, they may provide important functional insight given their key role in neural functions, and represent an important avenue of research in the study of epigenetic mechanisms in FASD. Finally, covalent modifications to mRNA and different ncRNA species are emerging as important regulatory mechanisms in the brain. In particular, levels of N^6^-methyladenosine increase in the prefrontal cortex of mice following behavioral training, suggesting a potential role in cognitive functions \[[@B130]\]. While the functional implications of these modifications remain unclear, they may prove important in alcohol-induced deficits given their abundance in the brain. Overall, ncRNA appears to play important roles in the development of deficits associated with PAE, including facial dysmorphisms, neuroapoptosis and altered neurodevelopment, supporting a vital role in the etiology of deficits associated with FASD.

Important considerations for epigenetic studies of FASD {#S0006}
=======================================================

Although much headway has been made in characterizing the epigenetic patterns associated with developmental alcohol exposure and their role in fetal programming, a number of key considerations will be crucial for the next wave of epigenetic studies in FASD. First, most studies of alcohol exposure focus exclusively on male animals or do not highlight sex-specific differences, an issue found throughout many research fields and recently highlighted by the new funding guidelines from the National Institutes of Health \[[@B131]\]. Since epigenetic patterns are highly associated with sex, this further reduces the generalizability and applicability of findings from animal models of PAE to clinical settings \[[@B132]\]. This is particularly relevant to the domain of FASD, as males typically display different cognitive and behavioral phenotypes, as well as differential susceptibilities to stressors and mental health disorders compared with their female counterparts \[[@B133]\]. As such, the paucity of data on females in the FASD research field must be addressed in order to fully assess the role of epigenetics in the etiology of alcohol-induced deficits. Given the wide variety of PAE models, we must also begin to integrate findings from different models of exposure, which vary in terms of dosage (low to high), pattern of exposure (acute or chronic), trimester of exposure and type of ethanol administration, to identify the most robust epigenetic signatures of PAE (for a review on the different models of developmental alcohol exposure, please refer to \[[@B136]\]).

Additionally, a large portion of whole-genome analyses of epigenomic patterns have been performed either in cell culture or whole brains, which does not necessarily reflect the downstream functional implications of alcohol-induced alterations. Future studies should begin to assess changes within specific brain structures and primary tissues to further dissect the role of epigenetics in the various deficits associated with developmental alcohol exposure. Cell type differences must also be taken into account when analyzing epigenetic data, as cell type composition is a major driver of epigenetic patterns and may be altered by alcohol exposure. Various strategies can be used to address this issue, including the isolation of single cell types prior to epigenetic analyses, the inclusion of cell type proportions in statistical models, or bioinformatic methods such as cell type deconvolution and surrogate variable analysis. In addition, robust statistical methods must be used in the analysis of genome-wide alterations to prevent spurious associations with alcohol exposure. These considerations include the use of multiple-test correction and other methods to correct for discrepancies between groups (age, ethnicity, smoking, etc.), which tend to occur frequently in population studies of epigenetic mechanisms. Of note, the phenotypes associated with FASD have been rather heterogeneous in human studies, and possibly confounded with genetic ancestry, highlighting our need for large and diverse cohorts to tease apart the often subtle influences of PAE on the epigenome and identify critical periods of vulnerability.

Finally, to fully assess the role of epigenetic mechanisms in PAE-induced associated physiological functions, we must begin to integrate the multiple layers of epigenetic machinery, from chromatin alterations and DNA methylation to miRNA and lncRNA expression \[[@B39]\]. Future studies should also assess the concordance of these changes with mRNA expression, as the relationship between epigenetic patterns and transcription is highly complex and has yet to be fully elucidated. Although some studies of PAE have already begun to fill this niche, much work is needed before we can successfully integrate the multiple layers of genome-wide epigenomic regulation in the etiology of FASD \[[@B68],[@B69]\].

Future perspective {#S0007}
==================

Although the study of epigenetic patterns following PAE is progressing at a rapid rate, a number of key issues remain elusive in regard to both mechanisms of fetal programming and biomarkers of FASD. For one, early evidence from some groups suggests that developmental alcohol exposure could potentially have lasting impacts on the epigenome of future generations, suggesting a possible role for inter- or transgenerational epigenetic inheritance \[[@B91]\]. While these data are certainly intriguing and raise important ethical considerations in the study and prevention of FASD, they must be interpreted with relative caution due to severe limitations in studying such effects. First, the interpretation of these results must take into consideration the number of generations to determine whether they are considered inter or transgenerational, which are commonly confounded due to the presence of cells for the F2 generation in the pregnant F0 female \[[@B137]\]. Second, these studies were largely performed in rodent models, which have not yet been shown to display the same inheritance patterns as humans. Third, no cohorts are currently available for the study of transgenerational inheritance in humans, and the current evidence remains tenuous at best. Nevertheless, although much work must be done to fully assess the implications of inter- or transgenerational epigenetic inheritance in FASD, this remains an intriguing and important area of research that certainly warrants further investigation.

Another issue facing the field is that as of yet, and perhaps not surprisingly at this time, the vast majority of epigenetic studies rely on correlation, rather than causation. More specifically, even though epigenetic mechanisms are correlated with PAE in cross-sectional clinical cohorts and animal models, it is not yet clear whether their reversal would dampen PAE phenotypes, which would indicate a more causal role. Moreover, although epigenetic patterns appear to associate with changes in transcription, the majority of these relationships show inconsistent results across studies and the functional implications of epigenetic changes have yet to be fully established \[[@B45],[@B138]\]. As such, prior to making inferences concerning cognitive, behavioral or physiological outcomes from alcohol-induced epigenetic alterations, we must first establish a direct line of evidence between epigenetic patterns, gene expression profiles, and the phenotype in question, either through genetic manipulation of model organisms or therapeutic interventions. Given that different environmental factors have been shown to modulate PAE-induced deficits, including stress, immune challenges, or early-life adversity, futures studies must also begin to address the differences and similarities between basal and inducible alterations to gene expression and epigenetic patterns. Model organisms, such as mice, rats, zebrafish, and others will play a crucial role in addressing this issue, as they allow for finer manipulations of biological systems and tighter control of environmental conditions. Perhaps most importantly, we must begin to position epigenetic mechanisms at the nexus of exposure paradigms and phenotypic outcomes to provide better insight into the etiology of FASD. Furthermore, analysis of both central and peripheral tissues in animal models will be vital before we can begin to make functional inferences in clinical models, as human epigenetic studies mainly rely on peripheral tissues such as BEC and blood.

Although the degree to which peripheral alterations are linked to the mechanisms underlying FASD remains unknown, they may present a unique opportunity to develop accurate epigenetic biomarkers of PAE. In many cases, the deficits associated with FASD only become evident long after exposure, highlighting the importance of early biomarkers as tools to identify at-risk children and mitigate the long-term effects of alcohol. More recent studies in animal models and clinical populations of individuals with FASD are beginning to provide a solid foundation for biomarker discovery with hopes for definitive markers in the relatively near future. Of the utmost importance in this line of research are additional studies to validate current findings and to begin to assess the accuracy and specificity of these types of markers. While a characteristic epigenomic signature appears to occur in the buccal cells of children with FASD, this finding requires additional validation and testing in a clinical setting \[[@B78]\]. Furthermore, strong correlations have been identified between genetic background and epigenetic patterns, particularly in the case of gene by environment (GxE) interactions \[[@B139]\]. Given the challenges in obtaining cohorts of children with homogenous ethnicities, it will be vital to assess the relevance and implications of methylation quantitative trait loci or allelic variants correlating with nearby CpG methylation levels in the context of FASD. Longitudinal studies will also be integral to the identification of PAE-associated alterations to epigenetic profiles, as cross-sectional studies may not fully reflect the diversity of individuals with FASD across development and aging. Importantly, the field must also begin to move beyond early life outcomes and extend its focus into adolescence and adulthood, as data on adolescents and adults with FASD remains sparse. These studies will further develop a role for altered epigenetic programming in FASD and long-term health outcomes, be they immune, neurological or stress-related \[[@B15]\]. In addition, these may prove crucial to our understanding of the etiology of FASD, particularly given the relationship between aging, disease, and DNA methylation \[[@B142]\]. These longitudinal cohorts will also be necessary to assess the persistence of epigenetic reprogramming by PAE and the potential validity of biomarkers over time. Epigenetic profiles may also serve as a better marker of FASD if they are developed in conjunction with different stratification tools, such as MRI, eye tracking, physical and mental health diagnostics, and immune markers, to parse out the wide range of deficits associated with FASD and create more accurate diagnostic tools. Finally, we must also begin to assess the overlaps, or lack thereof, in epigenetic patterns among different neurodevelopmental disorders, as they may display similar deficits and share common or overlapping molecular etiologies \[[@B143]\]. The integration of these findings will provide important insight into the root cause of these disorders and may provide additional strategies for both diagnostic tools and therapeutic interventions.

Conclusion {#S0008}
==========

Despite the recognition of FAS over 40 years ago, PAE remains a leading cause of developmental disability in the developed world, as recent North American estimates place the incidence between 2 and 5% \[[@B144]\]. However, early identification of individuals with FASD remains difficult, limiting the effectiveness of current interventions, which still lack specific molecular or neurobiological targets \[[@B149]\]. Although the study of epigenetic patterns in FASD remains a emerging field, it has provided important contributions to our understanding of the molecular underpinnings of FASD. To date, epigenetic research has identified numerous alterations in DNA methylation patterns, chromatin states and ncRNA expression levels, which provide important biological insight into the deficits associated with FASD, while also potentially uncovering targets for therapeutic intervention. This work has begun to lay the groundwork for the development of epigenetic biomarkers of PAE, which may be the key to identifying children at risk for FASD. In turn, the identification of valid biomarkers will eventually support the creation of strategies for earlier diagnoses and targeted interventions to improve the lives of children and families affected by FASD.

###### Executive summary

-   Prenatal alcohol exposure (PAE) reprograms physiological systems, which may increase vulnerability to adverse behavioral and health outcomes.

-   The fetal programming effects of PAE could be explained by alterations to epigenetic mechanisms, such as DNA methylation, chromatin modifications and noncoding RNA.

-   Considerations for future epigenetic studies of fetal alcohol spectrum disorder (FASD) include the assessment of sex differences, reconciliation of different exposure paradigm and integration of multiple layers of epigenetic regulation.

-   Longitudinal studies of individuals with FASD will be imperative to identify potential inter- and trans-generational inheritance patterns, to elucidate the persistence of deficits in adolescents or adults and to develop of diagnostic tools for FASD.

-   Animal models will be crucial to establishing a causal link between epigenetic alterations, gene expression and the deficits caused by PAE.

-   In conjunction with different stratification tools, such as MRI, eye tracking, physical and mental health diagnostics, and immune markers, epigenetic mechanisms may prove key to the development of accurate diagnostic tools for FASD.
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